2022年9月9日至13日，一年一度的欧洲肿瘤内科学会（ESMO）年会在浪漫之都——法国巴黎举行。这是新冠疫情两年后，ESMO大会首次“回归现场”。本次大会共收到近3400篇投稿，会议上展示了1913篇摘要，以及76份重磅研究的LBA摘要。正如大会主题：“了解疾病，为癌症患者提供更优照护（Understanding the disease to provide better care for cancer patients）”一样，ESMO已成为全球肿瘤学交流的重要平台。ESMO大会明年将移师欧洲之门——马德里。《肿瘤瞭望》在本次大会现场采访了ESMO候任主席、西班牙巴伦西亚大学Andrés Cervantes教授。
《肿瘤瞭望》：这次ESMO大会上，有哪些研究引起了您的注意？
Dr Cervantes：我认为这是一次令人难以置信的会议，有很多非常重要的演讲。回想昨天在全体大会上，一项黑色素瘤试验表明新辅助治疗优于术后治疗。这是非常重要的，而且，前一天，我们听到了一项令人印象深刻的使用肿瘤浸润淋巴细胞的细胞治疗试验，显示出比免疫治疗剂更好的效果。昨天，一篇关于局部晚期结肠癌微卫星不稳定性的报告显示，免疫检查点抑制能够诱导大多数患者的病理完全缓解。这些是非常重要的发现，将在不久的将来改变我们的肿瘤学实践。
I think this is an incredible meeting with a lot of very important presentations.Thinking back to yesterday at the Presidential Session，having a melanoma trial showing that neoadjuvant treatment is better than post-operative treatment.That is very important，Also，the previous day，we heard an impressive trial on cell therapies using tumor-infiltrating lymphocytes，showing a better effect than immunotherapeutic agents.And yesterday，a presentation on locally advanced colon cancer with microsatellite instability showing that checkpoint inhibition was able to induce a pathological complete remission in the majority of patients.Those are very important findings that are going to shape the way we practice oncology in the near future.
《肿瘤瞭望》：您在胃癌HER2耐药机制方面做了很多研究工作，我们知道近年来HER2 ADCs有不少突破，您认为这类药物是HER2耐药患者的理想选择吗？
Dr Cervantes：我认为抗体偶联药物（ADCs）是一种非常聪明的化疗方法，因为它更特异。你需要能够连接到细胞表面的抗体，导入ADC药物后会释放化疗药物或附着的有毒化合物。我们有HER2扩增肿瘤的重要数据。有一种特殊的ADC非常有效，不仅可以治疗这种分子改变的患者，还可以挽救那些最初用标准抗体治疗的患者，随着疾病的进展，这些ADC能够产生重要的反应。我们有几个这样的ADC，在这次会议上，有一些关于它们的介绍。我认为这对HER2扩增的癌症患者来说意味着更好的未来。
I think antibody-drug conjugates(ADCs)are a very clever way of delivering chemotherapy，because it is more specific.You need an antibody.That antibody is going to link to the cell surface，and then by internalization，it is going to release the chemotherapy or the toxic compound that is attached.We have very important data in HER2-amplified tumors.There is one particular ADC that is very potent，not only to treat patients with this molecular alteration，but also to rescue or salvage those who were initially treated with standard antibodies，and as the disease progresses，these ADCs are able to produce important responses.We have several of these ADCs，and at this conference，there are some presentations on them.I think this means a better future for patients with cancers with HER2 amplifications.
《肿瘤瞭望》：作为ESMO候任主席，您对未来的ESMO发展和ESMO大会举行有什么展望，尤其是在新冠疫情的影响下？
Dr Cervantes：明年，ESMO大会将在马德里举行。我们还将期望我们能够传播大量的摘要和新的科学报告。每年我们都能获得如此大量的高质量摘要，这看起来是一个奇迹。我们知道ESMO是一个公认的平台，可以向社会传播这些新发现，明年也将非常成功。
Next year，ESMO will be in Madrid.We will also expect a large number of abstracts and new science that we can disseminate.It looks like a miracle that every year we are able to get such impressive amounts of abstracts of such good quality.We hope，knowing that ESMO is a well-recognized platform to communicate and transmit to the Society these new findings，that next year will also be very successful.
Andrés Cervantes教授
西班牙瓦伦西亚大学的医学教授
西班牙瓦伦西亚大学医院肿瘤内科主任
欧洲医学肿瘤学会（ESMO）主席（2020-2022）
ESMO临床实践指南中胃肠癌委员会主席